Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy
Open Access
- 12 January 2010
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 59 (4), 1046-1054
- https://doi.org/10.2337/db09-1336
Abstract
Cannabinoid receptor 1 (CB1) is localized in the central nervous system and in peripheral tissues involved in energy metabolism control. However, CB1 receptors are also expressed at low level within the glomeruli, and the aim of this study was to investigate their potential relevance in the pathogenesis of proteinuria in experimental type 1 diabetes. Streptozotocin-induced diabetic mice were treated with N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,3-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251), a selective CB1-receptor antagonist, at the dosage of 1 mg · kg−1 · day−1 via intraperitoneal injection for 14 weeks. Urinary albumin excretion was measured by enzyme-linked immunosorbent assay. CB1 receptor expression was studied by immunohistochemistry, immunoblotting, and real-time PCR. Expression of nephrin, podocin, synaptopodin, and zonula occludens-1 (ZO-1) was assessed by immunofluorescence and real-time PCR. Fibronectin, transforming growth factor-β1 (TGF-β1), and connective tissue growth factor (CTGF) mRNA levels were quantitated by real-time PCR. In diabetic mice, the CB1 receptor was overexpressed within the glomeruli, predominantly by glomerular podocytes. Blockade of the CB1 receptor did not affect body weight, blood glucose, and blood pressure levels in either diabetic or control mice. Albuminuria was increased in diabetic mice compared with control animals and was significantly ameliorated by treatment with AM251. Furthermore, CB1 blockade completely prevented diabetes-induced downregulation of nephrin, podocin, and ZO-1. By contrast overexpression of fibronectin, TGF-β1, and CTGF in renal cortex of diabetic mice was unaltered by AM251 administration. In experimental type 1 diabetes, the CB1 receptor is overexpressed by glomerular podocytes, and blockade of the CB1 receptor ameliorates albuminuria possibly via prevention of nephrin, podocin, and ZO-1 loss.Keywords
This publication has 40 references indexed in Scilit:
- Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosisKidney International, 2008
- Peripheral, but Not Central, CB1 Antagonism Provides Food Intake–Independent Metabolic Benefits in Diet-Induced Obese RatsDiabetes, 2008
- Effect of cannabidiol on sepsis‐induced motility disturbances in mice: involvement of CB1 receptors and fatty acid amide hydrolaseNeurogastroenterology & Motility, 2008
- Targeting the endocannabinoid system: to enhance or reduce?Nature Reviews Drug Discovery, 2008
- High glucose induction of DNA-binding activity of the transcription factor NFκB in patients with diabetic nephropathyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2008
- The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker ratsNeuropharmacology, 2008
- Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet β-cells via CB1 receptorsRegulatory Peptides, 2008
- Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker ratsKidney International, 2007
- The expression of receptors for endocannabinoids in human and rodent skeletal muscleBiochemical and Biophysical Research Communications, 2007
- Activation of Human T Cells Induces Upregulation of Cannabinoid Receptor Type 1 TranscriptionNeuroimmunomodulation, 2007